Dinesh Khanna1, Harsh Agrawal, Philip J Clements. 1. David Geffen School of Medicine at UCLA, 1000 Veteran Avenue, Room 32-59 Rehabilitation Building, Los Angeles, CA 90095, USA. dkhanna@mednet.ucla.edu
Abstract
OBJECTIVE: EF is a rare fibrosing disorder that may involve skin and internal organs. Current therapies include moderate- to high-dose glucocorticoids with or without use of immunosuppressives. METHODS: We report three cases of steroid-resistant EF in clinical practice who were treated with 3 mg/kg every 8 weeks infliximab therapy. RESULTS: All patients noticed an improvement in their symptoms, joint contractures and skin thickening within 8 weeks of starting infliximab therapy, ultimately leading to a drug-free remission (range 1-3 years). CONCLUSION: Based on this and other reported cases, infliximab may be beneficial in patients with steroid-resistant EF.
OBJECTIVE: EF is a rare fibrosing disorder that may involve skin and internal organs. Current therapies include moderate- to high-dose glucocorticoids with or without use of immunosuppressives. METHODS: We report three cases of steroid-resistant EF in clinical practice who were treated with 3 mg/kg every 8 weeks infliximab therapy. RESULTS: All patients noticed an improvement in their symptoms, joint contractures and skin thickening within 8 weeks of starting infliximab therapy, ultimately leading to a drug-free remission (range 1-3 years). CONCLUSION: Based on this and other reported cases, infliximab may be beneficial in patients with steroid-resistant EF.
Authors: Anna Drosou; Robert S Kirsner; Esperanza Welsh; Tory P Sullivan; Francisco A Kerdel Journal: J Cutan Med Surg Date: 2003-09-24 Impact factor: 2.092
Authors: C P Denton; M Engelhart; N Tvede; H Wilson; K Khan; X Shiwen; P E Carreira; F Diaz Gonzalez; C M Black; F H van den Hoogen Journal: Ann Rheum Dis Date: 2008-09-09 Impact factor: 19.103
Authors: Maria Ester Simeira Fonseca; Maria Victória Quaresma; Ana Paula Luppino-Assad; Henrique Carriço da Silva; Danieli Castro O Andrade; Percival D Sampaio-Barros Journal: Rheumatol Int Date: 2017-12-15 Impact factor: 2.631
Authors: Jorre S Mertens; Marieke M B Seyger; Rogier M Thurlings; Timothy R D J Radstake; Elke M G J de Jong Journal: Am J Clin Dermatol Date: 2017-08 Impact factor: 7.403